---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-018896"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2026-05-29T20:56:34+00:00"
generated_at: "2026-05-29T20:57:37.883378+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Monopar presents Phase 2 data for ALXN1840 in Wilson disease at EASL 2026

## Summary
- ALXN1840 (tiomolibdate choline) Phase 2 study results presented at EASL International Liver Congress 2026.
- Study evaluated effect on liver pathology and clinical symptoms in Wilson disease patients.
- No specific efficacy or safety figures provided in the 8-K text; presentation is an image exhibit.

## SEC filing metadata
- accession: 0001437749-26-018896
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2026-05-29T20:56:34+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774926018896/0001437749-26-018896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774926018896/mnpr20260529_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-018896
- JSON: https://secwatch.observer/filing/0001437749-26-018896.json
- Plain text: https://secwatch.observer/filing/0001437749-26-018896.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.